RecruitingNCT06693440
The Immune Assessment of PD-1 Antibody Therapy in Tumor
The Immune Assessment of PD-1 Antibody Therapy in Tumor - A Case-Control Study
Sponsor
Quanli Gao
Enrollment
3,000 participants
Start Date
Jul 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥18 years.
- Pathologically confirmed malignant tumors.
- Complete medical records.
- Assessable immune function test data.
Exclusion Criteria4
- Age <18 years.
- No confirmed tumor pathology.
- Untraceable medical records.
- Non-assessable immune function tests.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPD-1 Inhibitors
Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06693440
Related Trials
Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions
NCT052826542 locations
Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort
NCT0586210318 locations
Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
NCT070983511 location
Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
NCT069153891 location
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
NCT032643521 location